Antibiotics are compounds of natural, semi-synthetic, or synthetic origin which inhibit growth of microorganisms without significant toxicity to the human or animal host. A key mode of action for antibiotics is to interfere with cell wall, nucleic acid or protein synthesis.  They can be grouped according to the microorganisms they act primarily against such as antibacterials, antifungals or antivirals.

The world is running out of antibiotics. Between 1940 and 1962, more than 20 new classes of antibiotics were marketed. Since then, only two new classes have reached the market. Analogue development kept pace with the emergence of resistant bacteria until 10–20 years ago. Now, not enough analogues are reaching the market to stem the tide of antibiotic resistance, particularly among gram-negative bacteria.
Our studies demonstrate:

  • Antibiotic activity of cationic NanoGlys™ modifications
  • NanoGlys™ – drug conjugates maintain activity whilst improving other properties such as solubility, bioavailability or stability of drugs
  • Combinations of existing drugs and certain modified forms of NanoGlys™ have higher efficacy